Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616 · see citing works

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790 · see citing works

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324 · see citing works

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914 · see citing works

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676 · see citing works

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer, K., Barrett, J. R., Belij‐Rammerstorfer, S., Sharpe, H., Makinson, R., Morter, R., Flaxman, A. L., Wright, D., Bellamy, D. G., Bittaye, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-01194-5 · Cited by 577 · see citing works

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Tseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 555 · see citing works

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

McKay, P. F., Hu, K., Blakney, A. K., Samnuan, K., Brown, J. C., Penn, R., Zhou, J., Bouton, C. R., Rogers, P., Polra, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17409-9 · Cited by 462 · see citing works

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Wang, S., Tseng, S., Yen, C., Yang, J.-Y., Tsao, C.-H., Shen, C.-W., Chen, K.-H., Liu, F., Liu, W.-T., Chen, Y. A., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.090 · Cited by 421 · see citing works

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett, J. R., Belij-Rammerstorfer, S., Dold, C., Ewer, K. J., Folegatti, P. M., Gilbride, C., Halkerston, R., Hill, J., Jenkin, D., Stockdale, L., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01179-4 · Cited by 315 · see citing works

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Folegatti, P. M., Bittaye, M., Flaxman, A. L., Lopez, F. R., Bellamy, D. G., Kupke, A., Mair, C., Makinson, R., Sheridan, J., Rohde, C., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30160-2 · Cited by 230 · see citing works

Vaccines for COVID-19

Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N.-M., Pierce, B. F., Stirling, D. C., Wang, Z., & Pollock, K. M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13517 · Cited by 222 · see citing works

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens

Antrobus, R., Coughlan, L., Berthoud, T. K., Dicks, M. D. J., Hill, A. V. S., Lambe, T., & Gilbert, S. C. (2013) · Molecular Therapy · doi:10.1038/mt.2013.284 · Cited by 197 · see citing works

Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer

Blakney, A. K., Zhu, Y., McKay, P. F., Bouton, C. R., Yeow, J., Tang, J., Hu, K., Samnuan, K., Grigsby, C. L., Shattock, R. J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00326 · Cited by 155 · see citing works

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Graham, S., McLean, R., Spencer, A. J., Belij-Rammerstorfer, S., Wright, D., Ulaszewska, M., Edwards, J., Hayes, J. W. P., Martini, V., Thakur, N., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-00221-3 · Cited by 126 · see citing works

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

Ewer, K., Sebastian, S., Spencer, A. J., Gilbert, S. C., Hill, A. V. S., & Lambe, T. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1383575 · Cited by 85 · see citing works

A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice

Silva-Cayetano, A., Foster, W. S., Innocentin, S., Belij-Rammerstorfer, S., Spencer, A. J., Burton, O. T., Fra-Bidó, S., Le Lee, J., Thakur, N., Conceicao, C., et al. (2021) · Med · doi:10.1016/j.medj.2020.12.006 · Cited by 84 · see citing works

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

Venkatraman, N., Ndiaye, B., Bowyer, G., Wade, D., Sridhar, S., Wright, D., Powlson, J., Ndiaye, I., Dièye, S., Thompson, C., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy639 · Cited by 79 · see citing works

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaquesPreprint

van Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.09.426058 · Cited by 50 · see citing works

Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study

Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., Heath, R., Turner, A., Friedrich, Z., Morrison, L., et al. (2021) · doi:10.2139/ssrn.3796835 · Cited by 27 · see citing works

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Liu, X., Shaw, R. H., Stuart, A. S. V., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E., Collins, A. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01694-9 · Cited by 478 · see citing works

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Clemens, S. A. C., Weckx, L. Y., Clemens, R. L., Mendes, A. V. A., Souza, A. R., Silveira, M. B. V., da Guarda, S. N. F., de Nobrega, M. M., Pinto, M. I. D. M., Gonzalez, I. G. S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00094-0 · Cited by 421 · see citing works

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Borobia, A. M., Carcas, A. J., Pérez‐Olmeda, M., Castaño, L. A., Bertran, M. J., García‐Pérez, J., Campins, M., Portolés, A., González-Pérez, M., Morales, M. T. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01420-3 · Cited by 350 · see citing works

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Hillus, D., Schwarz, T., Tober‐Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00357-x · Cited by 343 · see citing works

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Schmidt, T., Klemis, V., Schub, D., Mihm, J., Hielscher, F., Marx, S., Abu‐Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01464-w · Cited by 340 · see citing works

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works

Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination

Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J., Massardier-Pilonchery, A., et al. (2021) · Nature · doi:10.1038/s41586-021-04120-y · Cited by 212 · see citing works

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

Lapuente, D., Fuchs, J., Willar, J., Antão, A. V., Eberlein, V., Uhlig, N., Issmail, L., Schmidt, A. P., Oltmanns, F., Peter, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27063-4 · Cited by 213 · see citing works

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Fendler, A., Shepherd, S. T. C., Au, L., Wilkinson, K. A., Wu, M., Byrne, F., Cerrone, M., Schmitt, A. M., Joharatnam‐Hogan, N., Shum, B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00274-w · Cited by 170 · see citing works

Nanotechnology-based mRNA vaccines

Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 172 · see citing works

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?

Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 121 · see citing works

Quality by Design for enabling RNA platform production processes

Daniel, S., Kis, Z., Kontoravdi, C., & Shah, N. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.03.012 · Cited by 128 · see citing works

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Geers, D., Schmitz, K. S., Garrido, H. M. G., Koopmans, M., Dalm, V. A. S. H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116747 · Cited by 125 · see citing works

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients

Reindl‐Schwaighofer, R., Heinzel, A., Mayrdorfer, M., Jabbour, R., Hofbauer, T. M., Merrelaar, A. E., Eder, M., Regele, F., Doberer, K., Spechtl, P., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7372 · Cited by 123 · see citing works

Viral vector vaccines

McCann, N. S., O’Connor, D., Lambe, T., & Pollard, A. J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102210 · Cited by 123 · see citing works

To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination

Chiu, N., Chi, H., Tu, Y., Huang, Y.-N., Tai, Y., Weng, S.-L., Chang, L., Huang, D. T., Huang, F.-Y., & Lin, C. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1971522 · Cited by 117 · see citing works

COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts

Rashedi, R., Samieefar, N., Masoumi, N., Mohseni, S., & Rezaei, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27463 · Cited by 117 · see citing works

An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times

Montero, C. G., Fraile‐Μartinez, O., Bravo, C., Torres‐Carranza, D., Sánchez‐Trujillo, L., Gomez-Lahoz, A. M., Guijarro, L. G., García‐Honduvilla, N., Asúnsolo, Á., Buján, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050433 · Cited by 109 · see citing works

Animal models for COVID-19: advances, gaps and perspectives

Fan, C., Wu, Y., Xiong, R., Yang, Y., Ling, C., Liu, S., Liu, S., & Wang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01087-8 · Cited by 104 · see citing works

Viral Vectors for COVID-19 Vaccine Development

Lundstrom, K. H. (2021) · Viruses · doi:10.3390/v13020317 · Cited by 91 · see citing works

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Fendler, A., Au, L., Shepherd, S. T. C., Byrne, F., Cerrone, M., Boos, L. A., Rzeniewicz, K., Gordon, W., Shum, B., Gerard, C. L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00275-9 · Cited by 87 · see citing works

Self-Amplifying RNA Approach for Protein Replacement Therapy

Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76 · see citing works

A ‘mix and match’ approach to SARS-CoV-2 vaccination

Deming, M. E., & Lyke, K. E. (2021) · Nature Medicine · doi:10.1038/s41591-021-01463-x · Cited by 71 · see citing works

COVID ‐19: vaccination problems

Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15549 · Cited by 66 · see citing works

Humoral immune response after different SARS-CoV-2 vaccination regimens

Rose, R., Neumann, F., Grobe, O., Lorentz, T., Fickenscher, H., & Krumbholz, A. (2022) · BMC Medicine · doi:10.1186/s12916-021-02231-x · Cited by 62 · see citing works

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England

Powell, A. A., Power, L., Westrop, S. J., McOwat, K., Campbell, H. J., Simmons, R., Ramsay, M. E., Brown, K. E., Ladhani, S. N., & Amirthalingam, G. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.28.2100634 · Cited by 58 · see citing works

Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection

Rappaport, A., Hong, S., Scallan, C. D., Gitlin, L., Akoopie, A., Boucher, G. R., Egorova, M., Espinosa, J. A., Fidanza, M., Kachura, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31005-z · Cited by 57 · see citing works

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19

Silva-Pilipich, N., Beloki, U., Salaberry, L., & Smerdou, C. (2024) · Vaccines · doi:10.3390/vaccines12030318 · Cited by 57 · see citing works

A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity

Cafferty, S. M., Haque, A. K. M. A., Vandierendonck, A., Weidensee, B., Plovyt, M., Stuchlíková, M., François, N., Valembois, S., Heyndríckx, L., Míchiels, J., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.014 · Cited by 54 · see citing works

Acute Transverse Myelitis after COVID-19 Vaccination

Hsiao, Y.-T., Tsai, M., Chen, Y.-H., & Hsu, C.-F. (2021) · Medicina · doi:10.3390/medicina57101010 · Cited by 53 · see citing works

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

Khoo, N. K. H., Lim, J. M. E., Gill, U. S., de Alwis, R., Tan, N., Toh, J. Z. N., Abbott, J. E., Usai, C., Ooi, E. E., Low, J. G. H., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.004 · Cited by 47 · see citing works

State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses

Meir, J., Abid, M. A., & Abid, M. B. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.09.016 · Cited by 50 · see citing works

Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines

Zinatizadeh, M. R., Zarandi, P. K., Zinatizadeh, M., Yousefi, M. H., Amani, J., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112527 · Cited by 48 · see citing works

Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review

Garg, I., Sheikh, A. B., Pal, S., & Shekhar, R. (2022) · Infectious Disease Reports · doi:10.3390/idr14040057 · Cited by 44 · see citing works

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine

Nguyen, T. T., Quach, T. H. T., Tran, T. M., Phuoc, H. N., Nguyen, H. T., Vo, T. K., & Vo, G. V. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112650 · Cited by 41 · see citing works

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

Komori, M., Nogimori, T., Morey, A. L., Sekida, T., Ishimoto, K., Hassett, M. R., Masuta, Y., Ode, H., Tamura, T., Suzuki, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38457-x · Cited by 39 · see citing works

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial

Bánki, Z., Mateus, J., Rössler, A., Schäfer, H., Bante, D., Riepler, L., Grifoni, A., Sette, A., Simon, V. R., Falkensammer, B., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104073 · Cited by 34 · see citing works

Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion

Qin, Z., Bouteau, A., Herbst, C., & Igyártó, B. Z. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010830 · Cited by 38 · see citing works

DNA-Based Nonviral Gene Therapy─Challenging but Promising

Guan, X., Pei, Y., & Song, J. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00907 · Cited by 35 · see citing works

Heterologous vaccine regimens against COVID-19

Duarte‐Salles, T., & Prieto‐Alhambra, D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01442-2 · Cited by 33 · see citing works

Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges

Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 34 · see citing works

Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

Saunders, J. E., Gilbride, C., Dowall, S., Morris, S. J., Ulaszewska, M., Spencer, A. J., Rayner, E. L., Graham, V., Kennedy, E., Thomas, K. M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104523 · Cited by 33 · see citing works

Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety

Meng, H., Mao, J., & Ye, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27590 · Cited by 35 · see citing works

Review Article: vaccination for patients with inflammatory bowel disease during the COVID‐19 pandemic

Doherty, J., Fennessy, S., Stack, R., Morain, N. O., Cullen, G. J., Ryan, E. J., Gascun, C. F. D., & Doherty, G. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16590 · Cited by 28 · see citing works

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

Spencer, A. J., Morris, S. J., Ulaszewska, M., Powers, C., Kailath, R., Bissett, C., Truby, A., Thakur, N., Newman, J., Allen, E. R., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103902 · Cited by 29 · see citing works

The challenge of emerging SARS-CoV-2 mutants to vaccine development

Li, R., Liu, J., & Zhang, H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.001 · Cited by 24 · see citing works

SARS-CoV-2 immunity and vaccine strategies in people with HIV

Mullender, C., da Costa, K., Alrubayyi, A., Pett, S. L., & Peppa, D. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac005 · Cited by 22 · see citing works

Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies

D’Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091163 · Cited by 22 · see citing works

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccination

Hollstein, M. M., Münsterkötter, L., Schön, M. P., Bergmann, A., Husar, T. M., Abratis, A., Eidizadeh, A., Schaffrinski, M., Zachmann, K., Schmitz, Ä., et al. (2022) · Allergy · doi:10.1111/all.15247 · Cited by 21 · see citing works

The importance of booster vaccination in the context of Omicron wave

Wei, Z., He, J., Wang, C., Bao, J., Leng, T., & Chen, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.977972 · Cited by 22 · see citing works

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen

Gómez, C. E., Perdiguero, B., Usero, L., Marcos-Villar, L., Miralles, L., Leal, L., Sorzano, C. Ó. S., Sánchez-Corzo, C., Plana, M., García, F., et al. (2021) · Vaccines · doi:10.3390/vaccines9090959 · Cited by 21 · see citing works

The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data

Li, Z., Liu, X., Liu, M., Wu, Z., Liu, Y., Li, W., Liu, M., Wang, X., Gao, B., Luo, Y., et al. (2021) · Vaccines · doi:10.3390/vaccines9111328 · Cited by 20 · see citing works

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines

Elliott, T., Cheeseman, H. M., Evans, A. B., Day, S., McFarlane, L. R., O’Hara, J., Kalyan, M., Amini, F., Cole, T., Winston, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010885 · Cited by 21 · see citing works

The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta

Keikha, R., Hashemi-Shahri, S. M., & Jebali, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-00830-5 · Cited by 19 · see citing works

Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen

Casmil, I. C., Bathula, N. V., Huang, C., Wayne, C. J., Cairns, E. S., Friesen, J. J., Soriano, S. K. V., Liao, S., Ho, C., Kong, K. Y. S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.055 · Cited by 18 · see citing works

In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?

Echeverría, N., Comas, V., Aldunate, F., Perbolianachis, P., Moreno, P., & Cristina, J. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i10.1234 · Cited by 18 · see citing works

Immunogenicity and safety of an inactivated SARS‐CoV‐2 vaccine in people living with HIV: A cross‐sectional study

Cai, S., Liao, G., Yu, T., Gao, Q., Zou, L., Zhang, H., Xu, X., Chen, J., Lu, A., Wu, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27872 · Cited by 18 · see citing works

The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients

Fiorino, F., Ciabattini, A., Sicuranza, A., Pastore, G., Santoni, A., Simoncelli, M., Polvere, J., Galimberti, S., Baratè, C., Sammartano, V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017863 · Cited by 18 · see citing works

Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms

Reinke, S., Pantazi, E. D., Chappell, G. R., Sánchez-Martínez, A., Guyon, R., Fergusson, J. R., Salman, A. M., Aktar, A., Mukhopadhyay, E. S., Ventura, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101245 · Cited by 18 · see citing works

Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate

Marcellus, Voss, C. J. D., Li, S., Richard, A., Almujri, S. S., Ateere, A., Frank, G., Lemoine, C., McShane, H., & Stylianou, E. (2025) · Scientific Reports · doi:10.1038/s41598-024-84667-8 · Cited by 17 · see citing works

Effectiveness of COVID-19 Vaccination on Reduction of Hospitalizations and Deaths in Elderly Patients in Rio Grande do Norte, Brazil

Sales-Moioli, A. I. L., Galvão-Lima, L. J., Pinto, T. K. B., Cardoso, P. H., Silva, R. D., Fernandes, F. R. D. S., Barbalho, I. M. P., Farias, F. L. D. O., Veras, N. V. R., Souza, G. F. D. A., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192113902 · Cited by 17 · see citing works

The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2 1-180 ) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge

Utrilla-Trigo, S., Jiménez-Cabello, L., Calvo-Pinilla, E., Marín-López, A., Lorenzo, G., Sánchez-Cordón, P., Moreno, S., Benavides, J., Gilbert, S., Nogales, A., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01614-21 · Cited by 16 · see citing works

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

Rice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910136 · Cited by 15 · see citing works

The combined expression of the nonstructural protein NS1 and the N-terminal half of NS2 (NS21-180) by ChAdOx1 and MVA confers protection against clinical disease in sheep upon bluetongue virus challenge

Utrilla-Trigo, S., Jiménez-Cabello, L., Calvo-Pinilla, E., Marín-López, A., Lorenzo, G., Sánchez-Cordón, P. J., Moreno, S., Benavides, J., Gilbert, S. C., Nogales, A., et al. (2022) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · Cited by 15 · see citing works

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19

Agrati, C., Capone, S., Castilletti, C., Cimini, E., Matusali, G., Meschi, S., Tartaglia, E., Camerini, R., Lanini, S., Milleri, S., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00394-5 · Cited by 15 · see citing works

The oral vaccine based on self-replicating RNA lipid nanoparticles can simultaneously neutralize both SARS-CoV-2 variants alpha and delta

Mohammadi, G., Koranni, Z. S., & Jebali, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108231 · Cited by 15 · see citing works

Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashionPreprint

Qin, Z., Bouteau, A., Herbst, C., & Igyártó, B. Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.16.484616 · Cited by 15 · see citing works

Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine

Farahmand, B., Larijani, M. S., Fotouhi, F., Biglari, A., Sorouri, R., Amiri, F. B., Eslamifar, A., Jalali, T., Salehi-Vaziri, ‪., Banifazl, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20555 · Cited by 14 · see citing works

Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer

Debie, Y., Audenaerde, J. R. M. V., Vandamme, T., Croes, L., Teuwen, L.-A. M. N., Verbruggen, L., Vanhoutte, G., Marcq, E., Verheggen, L., Blon, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2185 · Cited by 14 · see citing works

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Sablerolles, R. S. G., Goorhuis, A., GeurtsvanKessel, C. H., de Vries, R. D., Huckriede, A. L. W., Koopmans, M., Lafeber, M., Postma, D. F., van Baarle, D., Visser, L. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753319 · Cited by 13 · see citing works

Reactogenicity After Heterologous and Homologous COVID-19 Prime-Boost Vaccination Regimens: Descriptive Interim Results of a Comparative Observational Cohort Study

Warkentin, L., Zeschick, N., Kühlein, T., Steininger, P. A., Überla, K., Kaiser, I., Gall, C. M., Sebastião, M., & Hueber, S. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-022-07443-x · Cited by 13 · see citing works

Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial

Heinzel, A., Schrezenmeier, E. V., Regele, F., Hu, K., Raab, L., Eder, M., Aigner, C., Jabbour, R., Aschauer, C., Stefanski, A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.936126 · Cited by 13 · see citing works

A relax-and-fix Pareto-based algorithm for a bi-objective vaccine distribution network considering a mix-and-match strategy in pandemics

Nikoubin, A., Mahnam, M., & Moslehi, G. (2022) · Applied Soft Computing · doi:10.1016/j.asoc.2022.109862 · Cited by 13 · see citing works

Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force

Tavares, A. C. F. M. G., de Melo, A. K. G., Cruz, V. A., de Souza, V. A., de Carvalho, J. S., Machado, K. L. L. L., Valadares, L. D. D. A., Neto, E. T. D. R., de Rezende, R. P. V., Guimarães, M. F. B. D. R., et al. (2022) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-022-00234-7 · Cited by 12 · see citing works

Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study

Andersson, N. W., Thiesson, E. M., Laursen, M. V., Mogensen, S. H., Kjær, J., & Hviid, A. P. (2022) · BMJ · doi:10.1136/bmj-2022-070483 · Cited by 12 · see citing works

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients

Chu, C., Schönbrunn, A., Fischer, D., Liu, Y., Hocher, J.-G., Weinerth, J., Klemm, K., von Baehr, V., Krämer, B. K., Elitok, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1187880 · Cited by 12 · see citing works

Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous RegimePreprint

Kant, R., Dwivedi, G. R., Zaman, K., Sahay, R. R., Sapkal, G. N., Kaushal, H., Nyayanit, D. A., Yadav, P. D., Deshpande, G. R., Singh, R., et al. (2021) · medRxiv · doi:10.1101/2021.08.06.21261716 · Cited by 12 · see citing works

Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency

Song, Y., Wang, J., Yang, Z., He, Q., Bao, C., Xie, Y., Sun, Y., Li, S., Quan, Y., Yang, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1406138 · Cited by 11 · see citing works

Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium

Marcos-Villar, L., Perdiguero, B., López‐Bravo, M., Zamora, C., Sin, L., Álvarez, E., Sorzano, C. Ó. S., Sánchez-Cordón, P. J., Casasnovas, J. M., Astorgano, D., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2387906 · Cited by 11 · see citing works

Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein

Manzoni, T. B., Westover, J. B., Lundgreen, K. A., Hicks, P. D., Petch, R. J., Ort, J. T., Weissman, D., Fan, S. H. Y., Hensley, S. E., Pardi, N., et al. (2025) · Viruses · doi:10.3390/v17081095 · Cited by 11 · see citing works

COVID-19 vaccination challenges: A mini-review

Afshar, Z. M., Barary, M., Hosseinzadeh, R., Karim, B., Ebrahimpour, S., Nazary, K., Sio, T. T. W., Sullman, M. J. M., Carson‐Chahhoud, K., Moudi, E., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2066425 · Cited by 11 · see citing works

Designing an integrated sustainable-resilient mix-and-match vaccine supply chain network

Jahed, A., Molana, S. M. H., Tavakkoli-Moghaddam, R. R., & Valizadeh, V. (2024) · Annals of Operations Research · doi:10.1007/s10479-024-06211-1 · Cited by 10 · see citing works

A sustainable vaccine supply-production-distribution network with heterologous and homologous vaccination strategies: Bi-objective optimization

Jahed, A., Molana, S. M. H., & Tavakkoli-Moghaddam, R. R. (2024) · Socio-Economic Planning Sciences · doi:10.1016/j.seps.2024.102113 · Cited by 10 · see citing works

Future Prospects, Approaches, and the Government’s Role in the Development of a Hepatitis C Virus Vaccine

Tabll, A. A., Sohrab, S. S., Ali, A. A., Petrovic, A., Srdarević, S. S., Siber, S., Glasnović, M., Smolić, R., & Smolić, M. (2023) · Pathogens · doi:10.3390/pathogens13010038 · Cited by 9 · see citing works

Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination

Bauswein, M., Peterhoff, D., Plentz, A., Hiergeist, A., Wagner, R., Gessner, A., Salzberger, B., Schmidt, B., & Bauernfeind, S. (2022) · iScience · doi:10.1016/j.isci.2021.103694 · Cited by 9 · see citing works

Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants

Balasubramaniyam, A., Ryan, E., Brown, D. R., Hamza, T., Harrison, W., Gan, M., Sankhala, R., Chen, W.-H., Martinez, E., Jensen, J., et al. (2022) · Vaccines · doi:10.3390/vaccines11010042 · Cited by 9 · see citing works

Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines

Gerhards, C., Thiaucourt, M., Hetjens, M., Haselmann, V., Neumaier, M., & Kittel, M. (2023) · Vaccines · doi:10.3390/vaccines11030701 · Cited by 8 · see citing works

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination

Barocci, S., Orlandi, C., Diotallevi, A., Buffi, G., Ceccarelli, M., Vandini, D., Carlotti, E., Galluzzi, L., Rocchi, M., Magnani, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10040491 · Cited by 8 · see citing works

Applications of self-replicating RNA

Lundstrom, K. H. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.006 · Cited by 7 · see citing works

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru

Vargas‐Herrera, N., Fernández-Navarro, M., Cabezudo, N. E., Soto-Becerra, P., Solis, G., Escobar-Agreda, S., Valencia, J. S., Pampa-Espinoza, L., Bado, R., Solari, L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268419 · Cited by 7 · see citing works

Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study

Narongkiatikhun, P., Noppakun, K., Chaiwarith, R., Winichakoon, P., Vongsanim, S., Suteeka, Y., Pongsuwan, K., Kusirisin, P., Wongsarikan, N., Fanhchaksai, K., et al. (2023) · Vaccines · doi:10.3390/vaccines11040715 · Cited by 7 · see citing works

Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19

Richardson, C. D. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00366-0 · Cited by 7 · see citing works

Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers

Romero-Ibarguengoitia, M. E., González‐Cantú, A., Hernández-Ruíz, Y. G., Armendariz-Vázquez, A. G., Rivera-Salinas, D., Montelongo-Cruz, L. P., Rio-Parra, G. F. D., Barco-Flores, I. A., González-Facio, R., & Sanz‐Sánchez, M. Á. (2022) · Vaccines · doi:10.3390/vaccines10030392 · Cited by 5 · see citing works

The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccinesPreprint

Rose, R., Neumann, F., Grobe, O., Lorentz, T., Fickenscher, H., & Krumbholz, A. (2021) · medRxiv · doi:10.1101/2021.07.09.21260251 · Cited by 5 · see citing works

Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model

Wongnak, R., Brindha, S., Oba, M., Yoshizue, T., Islam, M. D., Islam, M. M., Takemae, H., Mizutani, T., & Kuroda, Y. (2024) · Molecules · doi:10.3390/molecules29112676 · Cited by 4 · see citing works

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis

Kim, D. K., Jung, S. W., Moon, J., Jeong, K. H., Hwang, H. S., Kim, J. S., Lee, S. H., Kang, S.-Y., & Kim, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894700 · Cited by 4 · see citing works

The fast-track development of COVID-19 vaccines

El‐Maradny, Y. A., Ramadan, A. A., Chavda, V. P., Balar, P. C., & Redwan, E. M. M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00027-8 · Cited by 4 · see citing works

Immunogenicity and Safety of Inactivated SARS-CoV-2 Vaccine in People Living with HIV: A Cross-Sectional StudyPreprint

Cai, S., Liao, G., Yu, T., Gao, Q., Zou, L., Zhang, H., Xu, X., Chen, J., Lu, A., Wu, Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3912536 · Cited by 4 · see citing works

Randomized Immunogenicity and Safety Study of Heterologous Versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses Of Coronavac COVID-19 VaccinePreprint

Clemens, S. A. C., Weckx, L. Y., Clemens, R. L., Mendes, A. V. A., Souza, A. R., Silveira, M. V., da Guarda, S. N. F., de Nobrega, M. M., Pinto, M. I. D. M., Gonzalez, I. G. S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3989848 · Cited by 4 · see citing works

Heterologous ORFV–Ad26 vaccination broadens antibody breadth and amplifies cellular immunity against SARS-CoV-2 spike

Reguzova, A., Haug, V., Müller, M., Fandrich, M., Dulovic, A., & Amann, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1715442 · Cited by 3 · see citing works

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines

Elliott, T., Cheeseman, H. M., Evans, A. B., Day, S., McFarlane, L. R., O’Hara, J., Kalyan, M., Amini, F., Cole, T., Winston, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010885 · Cited by 21 · see citing works

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

Rice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910136 · Cited by 15 · see citing works

Heteologous saRNA-Prime, DNA Dual-Antigen-Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing AntibodiesPreprint

Rice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.29.470440

Enhanced Stromal Activation at the Injection Site Boosts Immune Responses in Heterologous SARS-CoV-2 VaccinationPreprint

Jeon, J. H., Kim, S., Kim, S. Y., Shin, K., Park, B., Chang, S., Kang, C., Kim, Y.-J., Park, J., Youk, S., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5099300

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Sheng, W., Chang, S., Lin, P., Hsieh, M., Chang, H., Cheng, C., Yang, H., Pan, C., Ieong, S., Chao, T., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.02.020 · Cited by 26 · see citing works